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Introduction: IGFBP-6 inhibits angiogenesis as well as proliferation and survival of rhab-
domyosarcoma cells. However, it promotes migration of these cells in an IGF-independent
manner.The IGF system is implicated in ovarian cancer, so we studied the effects of IGFBP-6
in ovarian cancer cells.
Methods: The effects of wild type (wt) and a non-IGF-binding mutant (m) of IGFBP-6 on
migration of HEY and SKOV3 ovarian cancer cells, which, respectively, represent aggres-
sive and transitional cancers, were studied. ERK and JNK phosphorylation were measured
by Western blotting.
Results: IGF-II, wt-, and mIGFBP-6 each promoted SKOV3 cell migration by 77–98%
(p< 0.01). In contrast, IGF-II also increased HEY cell migration to 155±13% of control
(p< 0.001), but wt-IGFBP-6 and mIGFBP-6 decreased migration to 62±5 and 66±3%,
respectively (p<0.001). In these cells, coincubation of IGF-II with wt but not mIGFBP-6
increased migration. MAP kinase pathways are involved in IGFBP-6-induced rhabdomyosar-
coma cell migration, so activation of these pathways was studied in HEY and SKOV3 cells.
Wt and mIGFBP-6 increased ERK phosphorylation by 62–99% in both cell lines (p<0.05).
Wt-IGFBP-6 also increased JNK phosphorylation by 139–153% in both cell lines (p<0.05),
but the effect of mIGFBP-6 was less clear. ERK and JNK inhibitors partially inhibited the
migratory effects of wt and mIGFBP-6 in SKOV3 cells, whereas the ERK inhibitor partially
restored wt and mIGFBP-6-induced inhibition of HEY cell migration. The JNK inhibitor had
a lesser effect on the actions of wtIGFBP-6 and no effect on the actions of mIGFBP-6 in
HEY cells.
Conclusion: IGFBP-6 has opposing effects on migration of HEY and SKOV3 ovarian cancer
cells, but activates MAP kinase pathways in both. Delineating the pathways underlying
the differential effects on migration will increase our understanding of ovarian cancer
metastasis and shed new light on the IGF-independent effects of IGFBP-6.
Keywords: insulin-like growth factor, insulin-like growth factor binding protein-6, ovarian cancer, migration, MAP
kinase
INTRODUCTION
The insulin-like growth factor (IGF) system has a key role in nor-
mal growth and development (1). IGF-I is regulated by growth
hormone and mediates many of its actions, whereas both IGF-
I and IGF-II stimulate proliferation, survival, and migration of
many cell types. Dysregulation of the IGF system is implicated in
many disease processes including cancer, and there has been con-
siderable interest in recent years in developing IGF inhibitors as
therapeutic agents (2). However, clinical trials of these inhibitors
has been disappointing, and current strategies include under-
standing mechanisms of resistance as well as finding biomarkers
of IGF responsiveness that will permit optimized targeting of these
agents.
Insulin-like growth factor actions are regulated by a family of
six high affinity binding proteins (IGFBP 1–6) (3, 4). Of these,
IGFBP-6 is characterized by a 50-fold binding preference for IGF-II
over IGF-I, conferring specificity in inhibiting IGF-II actions (5–
7). Most IGFBPs also have IGF-independent actions, and we have
shown in recent years that IGFBP-6 inhibits angiogenesis (8) as
well as promoting migration of rhabdomyosarcoma and colon
cancer cells in an IGF-independent manner (9, 10). Further, we
identified cell surface prohibitin-2 as a protein that binds IGFBP-6
and is required for its effects on cell migration (11).
Ovarian cancer is the second most common gynecological
malignancy after uterine cancer but the most common cause of
gynecological cancer death in Australia (12). In the United States,
ovarian cancer is the eighth most common cancer and the fifth
leading cause of cancer death in women (13). The diagnosis of
ovarian cancer is often delayed because it presents with non-
specific symptoms, so that it has metastasized at presentation.
Because of this, 5-year-survival is 43%. The IGF system is impli-
cated in ovarian cancer, and both IGF ligands and the IGF-I
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receptor are expressed in this malignancy (14). In particular,
IGF2 gene expression was 300-fold higher in ovarian cancer tis-
sue than in normal ovarian tissue and expression was higher in
advanced stage poor prognosis cancers (15). IGFs have also been
shown to stimulate ovarian cancer cell invasion, proliferation, and
angiogenesis (16).
IGFBP-6 is commonly expressed at low levels in ovarian can-
cers (17). A single microarray study showed that IGFBP-6 mRNA
levels were lower in ovarian cancer tissue compared with non-
cancerous tissue (18); this may reflect derepression of IGF-II action
by decreased IGFBP-6, but levels were not confirmed in an inde-
pendent assay. Small studies of IGFBP-6 in serum of patients
with ovarian cancer are inconsistent (19, 20), which may reflect
methodological differences. The aim of this study was to determine
the effects of IGFBP-6 on migration of HEY, SKOV3, and OVCAR-
3 ovarian epithelial cancer cells, which, respectively, represent
aggressive, transitional, and less aggressive tumors.
MATERIALS AND METHODS
REAGENTS
Wild-type (wt) IGFBP-6 and a non-IGF-binding mutant
(Pro93/Ala, Leu94/Ala, Leu97/Ala, Leu98/Ala) were expressed as
His6-tagged proteins in E. coli, purified by Ni-NTA chromatog-
raphy, dialyzed against cell culture medium, and then stored
in aliquots at −80°C as previously described (9). Phosphatase
inhibitor mixtures 1 and 2 and signaling pathway inhibitors
PD98095 (for ERK1/2) and SP600125 (for JNK) were from
Sigma-Aldrich. Complete EDTA-free protease inhibitor mixture
tablets were from Roche Applied Science. Antisera to phospho-
ERK1/2 (Thr-204/Tyr-204), phospho-JNK (Thr-181/Tyr-185),
total ERK1/2 and JNK, and horseradish peroxidase-conjugated
donkey anti-rabbit IgG were from Genesearch (Arundel, Aus-
tralia). β-actin and PHB2 antisera were from Millipore (North
Ryde, Australia). SeeBlue Plus2 molecular weight markers were
obtained from Invitrogen.
CELL CULTURE
HEY, SKOV3, and OVCAR-3 cells, which, respectively, represent
aggressive, transitional, and less aggressive human ovarian cancers
(21), were used in the study. HEY cells are mostly mesenchymal
with a typical molecular signature (N-cadherin and vimentin pos-
itive, E-cadherin negative). SKOV3 cells are moderately epithelial,
with a flattened cobblestone appearance but a mesenchymal mol-
ecular signature (N-cadherin and vimentin positive, E-cadherin
negative). OVCAR-3 cells are slowest growing and are epithelial by
morphology and their molecular signature (E-cadherin positive,
vimentin negative). All cell lines were cultured in a 1:1 mixture
of Medium 199 and MCDB 105 (Sigma-Aldrich), supplemented
with 2 mM l-glutamine, 100 units/ml penicillin, 100µg/ml strep-
tomycin, 0.25µg/ml amphotericin B, and either 10% heat inac-
tivated bovine calf serum (complete culture medium, CCM) or
0.05% BSA (serum-free medium, SFM). Cells were seeded at
37°C, 5% CO2 for 24–48 h until they reached 70~80% conflu-
ence, followed by serum starvation for 16 h, and then subjected to
treatments for various times as specified, without or with IGFBP-6
(wt or mutant, 1µg/ml), IGF-II (100 ng/ml), and/or pathway
inhibitors (30µM).
CELL PROLIFERATION ASSAY
Cell number was measured after 72 h in serum-free medium using
an MTT assay as previously described (22).
CELL MIGRATION ASSAY
Migration assays were performed using a 48-well microchemotaxis
chamber (Neuroprobe, Cabin John, MD) as described previously
(9). Wt or mIGFBP-6 (1µg/ml) or IGF-II (100 ng/ml) in SFM
were added to the bottom well of the chamber. Polycarbonate fil-
ters (12µm pore size, coated with 100µg/ml gelatine in 10 mM
acetic acid at room temperature for 30 min) were placed over the
bottom wells, and cells (5× 104 cells/well) in SFM were seeded in
the top wells. In some experiments, pathway inhibitors PD98095
or SP600125 (30µM) in SFM were added to both bottom and
top chambers. After 16 h, the filter was removed, fixed with 100%
methanol for 5 min, and stained with 0.5% crystal violet, 50%
methanol for 20 min. The filter was then washed in water to
remove excess dye and unbound cells. After mounting the filter
on a glass slide, non-migrated cells on the top side of the filter
were completely removed. Three random fields per well were pho-
tographed,and migrating cells were counted using ImageJ software
(National Institutes of Health, Bethesda, MD, USA)1. Each data
point represents four to seven replicates.
PHOSPHORYLATION ASSAYS
Phosphorylation of MAP kinase pathway proteins was exam-
ined by Western blotting analysis. After treatment with wt- or
mIGFBP-6 for 10 min, cells were washed with cold PBS and lysed
in 10 mM Tris–HCl (pH 8.0), 0.1 M NaCl, 1 mM EDTA, 1% Tri-
ton X-100 containing protease inhibitors. Lysates were centrifuged
at 13,000 rpm for 5 min, supernatants collected and protein con-
centration determined. Proteins (60µg/lane) were separated by
SDS-10% PAGE and transferred onto nitrocellulose membranes.
Western blotting analyses were performed using antibodies against
phospho-ERK1/2 (1:2,000) or phospho-JNK (1:1,000). Follow-
ing an enhanced chemiluminescence reaction, membranes were
exposed to X-ray film. The membranes were then reprobed with
antisera to total ERK1/2 (1:2,000) or JNK (1:1,000), and finally β-
actin (1:10,000). Band intensities were quantitated using ImageJ
software.
STATISTICS
Results are shown as mean± SEM of three to nine independent
experiments as indicated. Data were analyzed by one-way or two-
way ANOVA as appropriate followed by Fisher’s PLSD test to
compare individual treatments.
RESULTS
IGFBP-6 HAS DIFFERENTIAL EFFECTS ON MIGRATION OF SKOV3 AND
HEY OVARIAN CANCER CELLS
Initially, the effects of IGF-II and wt or mIGFBP-6 on prolifera-
tion of ovarian cancer cells were studied. However, none of these
proteins had any effect on proliferation (results not shown). Cell
migration was then studied using a microchemotaxis chamber.
1http://imagej.nih.gov/ij
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FIGURE 1 | Effects of IGF-II and IGFBP-6 on SKOV3 and HEY cell
migration. Cells were placed in the upper well of a microchemotaxis
chamber, and migration across a membrane into the lower chamber
containing SFM± IGF-II (100 ng/ml), wt and/or mIGFBP-6 (1µg/ml) in the
lower wells was measured. Results are shown as a percentage of control
(mean±SEM, n=4–5 independent experiments). *p<0.05, **p<0.01,
***p<0.001 vs. Con; ##p<0.01 vs. wtIGFBP-6.
SKOV3 cell migration was increased by IGF-II (177± 19% of con-
trol, p< 0.01), wtIGFBP-6 (198± 22% of control, p< 0.001), and
mIGFBP-6 (195± 13% of control, p< 0.001) (Figure 1). Coincu-
bation of IGF-II with either wt or mIGFBP-6 had no additional
effect on migration of these cells. Collectively, these results suggest
that the effect of IGFBP-6 was IGF-independent.
Insulin-like growth factor-II also increased HEY cell migra-
tion to 155± 13% of control (p< 0.001) but wtIGFBP-6 and
mIGFBP-6 each decreased migration to 62± 5 and 66± 3% of
control, respectively (p< 0.001) (Figure 1). Coincubation of IGF-
II reversed the effect of wtIGFBP-6 to 95± 7% of control (p< 0.01
wtIGFBP-6 vs. wtIGFBP-6+ IGF-II). In contrast, coincubation
of IGF-II had no significant effect on the mIGFBP-6-induced
decrease in migration. These results suggest that the effect of
IGFBP-6 was IGF-dependent to some extent in these cells.
OVCAR-3 cells did not migrate under basal conditions or after
incubation with IGF-II or IGFBP-6 (results not shown) and were
not studied further.
IGFBP-6 INCREASES MAP KINASE ACTIVATION IN OVARIAN CANCER
CELLS
We have previously shown that MAP kinase pathways are involved
in IGFBP-6-induced rhabdomyosarcoma cell migration (9, 10), so
FIGURE 2 | IGFBP-6 increases phosphorylation of ERK in SKOV3 and
HEY cells. Following serum starvation overnight, SKOV3 and HEY cells
were treated without (con) or with wt or mIGFBP-6 (1µg/ml) for 10 min. Cell
lysates were subjected to Western blotting analysis using antibodies
against phospho-ERK. Blots were stripped and reprobed with total ERK.
β-actin was used as a protein loading control. (Upper): representative blots.
(Lower): extent of phosphorylation in response to wtIGFBP-6 and mIGFBP-6
was calculated as the ratio of phospho/total ERK. Results are shown as
mean±SEM of seven to nine independent experiments and expressed as
a percentage of control. *p< 0.05, **p<0.01, ***p<0.001 vs. Con.
we compared activation of these pathways in HEY and SKOV3
cells. Wt and mIGFBP-6, respectively, increased ERK phosphory-
lation in SKOV3 cells to 178± 15% (p< 0.01) and 199± 22%
(p< 0.001) of control (Figure 2). Similarly, wt and mIGFBP-
6, respectively, increased ERK phosphorylation in HEY cells to
162± 19% (p< 0.05) and 163± 24% (p< 0.05) of control.
wtIGFBP-6 also increased JNK phosphorylation in SKOV3 and
HEY cells to 253± 61% (p< 0.05) and 239± 66% (p< 0.05) of
control, respectively (Figure 3). In contrast, mIGFBP-6 signifi-
cantly increased JNK phosphorylation to 176± 19% (p< 0.001)
of control in SKOV3 cells but not in HEY cells (123± 13% of
control, NS).
Phosphorylation of p38 MAPK was not detected in either cell
line under basal conditions or following incubation with wt or
mIGFBP-6 (results not shown).
EFFECTS OF ERK AND JNK PATHWAY INHIBITORS ON
IGFBP-6-INDUCED MIGRATION IN OVARIAN CANCER CELLS
PD98059, an inhibitor of ERK1/2 activation, and SP600125, a
JNK inhibitor, were used to study the roles of MAPK pathways in
IGFBP-6-induced ovarian cancer cell migration. These inhibitors
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FIGURE 3 | IGFBP-6 increases phosphorylation of JNK in SKOV3 and
HEY cells. Following serum starvation overnight, SKOV3 and HEY cells
were treated without (con) or with wt mIGFBP-6 (1µg/ml) for 10 min. Cell
lysates were subjected to Western blotting analysis using antibodies
against phospho-JNK. Blots were stripped and reprobed with total JNK.
β-actin was used as a protein loading control. (Upper): representative blots.
(Lower): extent of phosphorylation in response to wtIGFBP-6 and
mIGFBP-6 was calculated as the ratio of phospho/total ERK. Results are
shown as mean±SEM of five to six independent experiments and
expressed as a percentage of control. *p<0.05, ***p<0.001 vs. Con.
were shown to, respectively, decrease ERK and JNK phosphoryla-
tion in each cell line at the concentration used (30µM, results not
shown).
In SKOV3 cells, neither inhibitor had a significant effect on
basal migration (Figure 4). PD98059 partially inhibited wtIGFBP-
6-induced migration from 347± 22 to 215± 24% of control
(p< 0.001). This inhibitor had a similar effect on mIGFBP-6-
induced migration (214± 5 vs. 353± 9% of control, p< 0.001).
SP600125 also partially abrogated SKOV3 cell migration induced
by wtIGFBP-6 (223± 16 vs. 347± 22% of control, p< 0.001) and
mIGFBP-6 (203± 18 vs. 353± 9% of control, p< 0.001).
In HEY cells, both inhibitors decreased basal migration by
~30% (p< 0.001, Figure 4). Despite this, PD98059 partially
restored migration in the presence of wtIGFBP-6 (83± 3 vs.
61± 3% of control,p< 0.001) and mIGFBP-6 (86± 2 vs. 65± 3%
of control, p< 0.001). SP600125 also partially restored migra-
tion in the presence of wtIGFBP-6 (74± 5 vs. 61± 3% of con-
trol, p< 0.01), although the effect was less potent than that
of PD98059 (p< 0.05). SP600125 had no effect on mIGFBP-6-
induced inhibition of HEY cell migration (64± 3 vs. 65± 3% of
control, NS).
FIGURE 4 | Effects of ERK and JNK inhibitors on IGFBP-6-induced
alterations in SKOV3 and HEY cell migration. Experiments were
performed in serum-free medium in the absence or presence of wt or
mIGFBP-6 (1µg/ml) in the lower wells and inhibitors (PD98059 and
SP600125, 30µM) in both the upper and lower wells of the chemotaxis
chamber. Results are shown as a percentage of control (mean±SEM of
three independent experiments). ***p< 0.001 vs. Con; ##p<0.01,
###p<0.001 vs. wtIGFBP-6; ˆˆˆp<0.001 vs. mIGFBP-6.
Since both inhibitors had partial effects on IGFBP-6-induced
changes in migration in each cell line, the effects of a combination
of the two inhibitors were studied to determine whether it would
completely abolish migration. However, the combination resulted
in significant toxicity in both cell lines (results not shown).
DISCUSSION
The findings of this study showed that IGFBP-6 increased migra-
tion of SKOV3 ovarian cancer cells in an IGF-independent manner,
which is similar to our previous findings in rhabdomyosarcoma
and colon cancer cells (9–11). However, in contrast to these cell
lines, IGFBP-6 inhibited migration of HEY ovarian cancer cells.
IGF-II reversed the inhibitory effects of wt but not mutant IGFBP-
6 in these cells, suggesting that IGFBP-6 inhibited migration by
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both IGF-dependent and IGF-independent mechanisms. Wt and
mutant IGFBP-6 increased ERK and JNK phosphorylation in both
cell lines, whereas mutant IGFBP-6 only increased ERK phos-
phorylation in HEY cells. Inhibitors of ERK and JNK partially
inhibited the migratory effects of wt and mIGFBP-6 in SKOV3
cells, whereas the ERK inhibitor partially restored wt and mIGFBP-
6-induced inhibition of HEY cell migration. The JNK inhibitor had
a lesser effect on the actions of wtIGFBP-6 and no significant effect
on the actions of mIGFBP-6 in HEY cells. The latter is consistent
with the lack of effect of mIGFBP-6 on JNK phosphorylation in
these cells.
We previously showed that IGFBP-6-induced migration of
rhabdomyosarcoma cells is dependent on activation of MAP
kinase pathways. In RD rhabdomyosarcoma cells, IGFBP-6 tran-
siently increased phosphorylation of p38 MAPK, whereas ERK
was constitutively activated and IGFBP-6 had no further effect (9).
Specific p38 and ERK inhibitors completely abolished mIGFBP-
6-induced RD cell migration as did p38 knockdown. In contrast,
the JNK pathway appeared to have no role in IGFBP-6-induced
migration of these cells. The pattern of MAPK activation was
different in Rh30 rhabdomyosarcoma cells, which derive from a
distinct tumor subtype (10). IGFBP-6 increased phosphorylation
of ERK and JNK, but had no effect on p38 phosphorylation in
these cells. ERK inhibition abolished mIGFBP-6-induced migra-
tion as did a p38 inhibitor, despite IGFBP-6 not inducing p38
phosphorylation. A JNK inhibitor also partially inhibited IGFBP-
6-induced Rh30 cell migration. These and other findings suggested
that crosstalk among MAP kinase pathways played an important
role in IGFBP-6-induced cell migration.
MAP kinases are also implicated in ovarian cancer cell migra-
tion. MAP4K4 increased SKOV3 cell migration via activation of
JNK but not ERK or p38 MAP kinases (23). ERK and JNK were also
implicated in mesothelin-stimulated migration of ovarian cancer
cells (24), whereas JNK but not ERK or p38 MAP kinase was
involved in GnRH-induced ovarian cancer migration (25). Inter-
estingly, the latter study included OVCAR-3 cells, which did not
migrate under any conditions in the current study; the reasons for
the different responses are unclear but may relate to specific tissue
culture conditions. Nevertheless, these findings are consistent with
the present study showing that MAP kinase inhibition decreases
IGFBP-6-induced migration of SKOV3 cells.
Although MAP kinase activation is associated with increased
migration of many cancer cell lines, they may also inhibit this
process in some circumstances. For example, ERK activation
inhibits neutrophil migration whereas p38 MAP kinase enhances
it (26). Similarly, ERK activation mediates CXCL1-induced inhibi-
tion of airway smooth muscle cell migration (27). These findings
are consistent with those of the present study showing that ERK
inhibition partially reversed IGFBP-6-induced inhibition of HEY
cell migration.
MAP kinase pathways are not the only signaling pathways
involved in cell migration. For example, the PI3 kinase/Akt path-
way also mediates migration of some cells (28) including ovarian
cancer cells (29). We performed preliminary time-course experi-
ments to determine the effects of wt and mIGFBP-6 on Akt phos-
phorylation. There was no effect in SKOV cells but there appeared
to be an increase in HEY cells (results not shown). However, these
results were highly variable and do not explain the inhibitory
effect of IGFBP-6 on HEY cell migration. Further, we have pre-
viously found that Akt was not involved in IGFBP-6-induced
rhabdomyosarcoma cell migration (10).
We showed that IGFBP-6-induced migration of rhabdomyosar-
coma cells is dependent on binding to prohibitin-2 (11). Knock-
down of prohibitin-2 abrogated IGFBP-6-induced migration of
these cells without perturbing IGFBP-6-induced phosphorylation
of ERK or JNK, suggesting that its effect was downstream or inde-
pendent of MAP kinases (11). The ovarian cancer cell lines used
in the present study express prohibitin-2 (results not shown), so it
would be of interest to determine whether this protein is involved
in the migratory responses observed in the present study.
Other IGFBPs have been shown to have context-specific differ-
ences in IGF-independent actions. For example, IGFBP-3 inhibited
or enhanced EGF-dependent proliferation of breast epithelial cells
depending on whether or not fibronectin was used to coat tissue
culture plates (30). In contrast with the present study, IGFBP-
3 also had differential effects on ERK phosphorylation in these
breast cells. A number of other studies have suggested that inter-
actions of IGFBP-3 with other modulators including GRP78 and
the sphingolipid rheostat may also play a role in these differential
responses (31). Future studies of potential interactions between
IGFBP-6 and these modulators would be of interest.
In conclusion, this study has shown differential effects of
IGFBP-6 on migration of two ovarian cancer cell lines. IGFBP-
6-dependent changes in migration of both cell lines were accom-
panied by MAP kinase pathway activation, so that this cannot
explain the opposite direction of the migratory responses. IGFBP-
6 inhibits the actions of IGF-II (7) and angiogenesis by an IGF-
independent pathway (8), and both of these may contribute to its
anti-tumorigenic effects. However, promotion of migration may
be pro-tumorigenic, so further studies to determine the mecha-
nisms underlying the differential effects of IGFBP-6 on migration
in these cell lines would help in developing an IGFBP-6-based ther-
apeutic for IGF-II-dependent cancers. These studies could include
determining differences in the molecular signatures of these cell
lines, which may in turn suggest additional potential therapeutic
targets and/or biomarkers of tumor aggressiveness. Metastasis is
a complex, multistage process, so studying the effects of IGFBP-6
on other aspects such as cell adhesion would also be of inter-
est. Finally, once the determinants of the promigratory actions
of IGFBP-6 are understood, combination therapies including an
“optimized” IGFBP-6 molecule and an IGF-I receptor inhibitor
may synergistically provide dual blockade of the IGF pathway
together with beneficial IGF-independent actions of the binding
protein.
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